Danaher Corporation

NYSE:DHR Stock Report

Market Cap: US$114.6b

Danaher Future Growth

Future criteria checks 2/6

Danaher is forecast to grow earnings and revenue by 19.9% and 5.5% per annum respectively. EPS is expected to grow by 18.7% per annum. Return on equity is forecast to be 11.4% in 3 years.

Key information

19.9%

Earnings growth rate

18.66%

EPS growth rate

Life Sciences earnings growth17.5%
Revenue growth rate5.5%
Future return on equity11.44%
Analyst coverage

Good

Last updated14 May 2026

Recent future growth updates

Recent updates

Narrative Update • May 02

DHR: Masimo Cash Acquisition Will Support Premium Future Earnings Multiple

Danaher’s updated analyst price target moves lower by about $8 per share to roughly $250, as analysts factor in more conservative assumptions for growth, profitability and future P/E multiples following a recent series of mostly downward target revisions across the Street. Analyst Commentary Recent research on Danaher reflects a mixed but generally cautious tone, with several price target cuts offset by one modest increase and a change in rating context at another company linked to Danaher’s pending acquisition activity.
Seeking Alpha • Apr 22

Danaher Q1 2026 Earnings Update

Summary Danaher had another somewhat uneventful quarter. Margin in biotechnology segment improved YoY to reach 42.7% in 1Q’26. Life Sciences segment’s core revenue grew at only 0.5% despite having an easy comp of -4% in 1Q’25. Management kept their core revenue guidance of ~3-6% but raised the high end of 2026 EPS guidance from $8.5 to $8.55. Read the full article on Seeking Alpha
New Narrative • Apr 20

Danaher Corporation (DHR): The Life Sciences Titan and the "Diagnostic Diversification" Shift

Danaher Corporation (DHR) , the global life sciences and diagnostics innovator, enters Tuesday, April 21, 2026 , following a mixed but resilient first-quarter earnings performance. Trading at $195.60 USD —a marginal 0.05% gain in a volatile post-earnings session—the stock is seeking firm support above its recent low of $181.01.
Narrative Update • Apr 16

DHR: Masimo Cash Deal Will Support Premium Future Earnings Multiple

Danaher’s analyst price target has been reset from about $264.91 to $257.73, as analysts factor in updated assumptions around profit margins, revenue growth, discount rates and future P/E, alongside mixed recent research that includes both target raises and cuts, as well as the planned Masimo acquisition. Analyst Commentary Recent research on Danaher reflects a split view, with some firms raising their price targets and others trimming them, while the planned Masimo acquisition sits at the center of many discussions about valuation and execution risk.
Narrative Update • Apr 01

DHR: Cash Deal For Masimo Will Support Premium Future Earnings Multiple

Analysts have nudged Danaher’s price targets higher by low double digit dollar amounts, pointing to updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the key drivers behind the revised dollar values. Analyst Commentary Recent research has focused on how Danaher’s valuation reflects expectations for future execution, especially in light of the planned Masimo acquisition and refreshed targets across the life science tools peer group.
Narrative Update • Mar 18

DHR: Cash Acquisition Will Support Re Rating And Premium Earnings Multiple

Analysts have nudged their price targets on Danaher higher by a few dollars into the mid $260s, citing a series of upward target revisions across the Street and support from the announced Masimo acquisition at $180 per share in cash. Analyst Commentary Recent research around Danaher has centered on the Masimo acquisition agreement at $180 per share in cash and a cluster of higher price targets that place the stock in the mid $260s to around $270.
Narrative Update • Mar 04

DHR: Masimo Cash Deal Will Support Re Rating And Premium Multiple

The analyst price target for Danaher has moved higher by a mid single digit dollar amount, reflecting updated assumptions for slightly stronger revenue growth and margins, alongside recent Street research that raised targets following the Masimo acquisition announcement and sector wide target adjustments. Analyst Commentary Recent Street research around Danaher reflects a mix of optimism on the Masimo acquisition and valuation, alongside a more cautious stance on deal terms and execution risk.
Narrative Update • Feb 17

DHR: Masimo Deal And Higher Future P/E Will Support Premium Multiple

Danaher’s updated analyst price target edges slightly lower to about $265, as analysts balance modest tweaks to revenue growth, profit margin and P/E assumptions with a broadly supportive run of recent target increases across the Street. Analyst Commentary Recent Street research on Danaher is clustered around higher price targets, with several bullish analysts lifting their numbers by single digit to low double digit dollar amounts.
Narrative Update • Feb 03

DHR: Higher Future P/E Assumptions Will Support Premium Multiple Through Soft 2026 Outlook

Analysts have nudged their average price target for Danaher higher, with our fair value estimate moving from US$261.50 to about US$265.23. This change is supported by a modestly higher assumed future P/E multiple and by Street research that has generally lifted targets in the life science tools sector.
Narrative Update • Jan 19

DHR: Share Repurchases And Soft 2026 Outlook Will Support Premium Multiple

Analysts have nudged their price targets on Danaher higher, reflected in a fair value update from US$259.23 to US$261.50, citing refreshed views on revenue growth, profit margins, and future P/E expectations in recent research. Analyst Commentary Recent price target moves on Danaher point to refreshed views on how the company could execute on growth plans, manage profitability, and justify its current P/E profile.
Narrative Update • Jan 05

DHR: Share Repurchases And Diagnostics Resilience Will Support Premium Multiple

Analysts have made a modest upward adjustment to their fair value estimate for Danaher to about US$259 from about US$258, reflecting slightly higher assumed profit margins and P/E, even as they highlight tempered expectations for 2025 and 2026 growth, ongoing uncertainty in China, and questions around how durable diagnostics demand will be. Analyst Commentary Analysts are split on Danaher, with some focusing on the valuation premium and others on the company’s ability to eventually reconnect with its historical growth profile.
Narrative Update • Dec 19

DHR: Share Repurchases Will Support Premium Multiple As Life Sciences Demand Recovers

Analysts modestly raised their blended fair value estimate for Danaher to about $258 from roughly $256, reflecting slightly lower discount rate and higher future multiple assumptions, even as they trim official price targets toward $220 amid ongoing uncertainty around the pace of life sciences and diagnostics recovery. Analyst Commentary Analysts broadly agree that Danaher's premium valuation assumes a reacceleration of growth across life sciences and diagnostics, but they remain divided on how quickly fundamentals will normalize versus the lingering headwinds in key end markets.
Narrative Update • Dec 04

DHR: Share Repurchases Will Support Premium Multiple Despite Slower Recovery Uncertainty

Danaher's fair value estimate has been nudged slightly higher to approximately $255.67 from about $254.20, as analysts balance still premium valuations and tempered growth expectations with signs of stabilization in key Life Sciences and Diagnostics markets. Analyst Commentary Recent Street research reflects a more balanced, wait and see stance on Danaher as investors weigh premium valuation levels against a slower growth trajectory and a gradual recovery in key end markets.
Narrative Update • Nov 20

DHR: Share Repurchases And Improving Profit Margins Will Drive Renewed Upside

Danaher's fair value estimate has edged slightly lower to $254.20 from $254.40, as analysts cite ongoing uncertainty in growth outlooks and mixed sector momentum. Analyst Commentary Recent analyst reports on Danaher reveal a mix of optimism around the company’s long-term positioning and concerns about near-term growth visibility and sector headwinds.
Narrative Update • Nov 04

DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds

Danaher’s fair value estimate has increased to $254.40 from $247.30. This reflects analysts’ view that while growth forecasts are now more gradual and discount rates slightly higher, the stock’s premium valuation still prices in a slow recovery and ongoing sector uncertainties.
Narrative Update • Oct 21

Analyst Commentary Highlights Mixed Sentiment and Minor Valuation Adjustments for Danaher

Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.
Narrative Update • Sep 11

Advanced Diagnostics And Personalized Therapies Will Expand Global Markets

Danaher’s consensus price target saw a marginal downward revision to $244.50 as analysts incorporate more conservative near-term estimates amid continued sector weakness and tempered recovery expectations, despite steady long-term fundamentals. Analyst Commentary Bearish analysts are lowering price targets due to "more realistic" multiples and sector-wide weakness in Life Sciences Tools and Diagnostics, with a cautious view on near-term healthcare stock performance.
Analysis Article • Aug 01

Some May Be Optimistic About Danaher's (NYSE:DHR) Earnings

Danaher Corporation's ( NYSE:DHR ) recent soft profit numbers didn't appear to worry shareholders, as the stock price...
Analysis Article • Jul 12

Is Danaher Corporation (NYSE:DHR) Trading At A 33% Discount?

Key Insights Danaher's estimated fair value is US$304 based on 2 Stage Free Cash Flow to Equity Current share price of...
Analysis Article • May 22

Is Danaher (NYSE:DHR) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Mar 31

Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations

Summary Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins face short-term pressure from China's VBP initiative, but cost-cutting measures and operational efficiency should drive long-term margin expansion. The stock is undervalued compared to historical levels, trading at a discount to its average forward P/E over the last five years. I maintain a buy rating on DHR stock due to its strong long-term growth prospects and attractive valuation. Read the full article on Seeking Alpha
Seeking Alpha • Mar 22

Danaher: Near 5-Year Low Is A Great Entry Point

Summary Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechnology, life sciences, and diagnostics, with robust profitability and free cash flow. Growth catalysts include advancements in bioprocessing, molecular diagnostics, and neurodegenerative disease detection, with expected EPS growth of 10%-13% annually over the next three years. Read the full article on Seeking Alpha
Seeking Alpha • Feb 17

Danaher: Self-Inflicted Pessimism?

Summary Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company’s strategic capital allocation, including share buybacks and acquisitions, suggests management is positioning for long-term value creation, despite short-term pessimism. Danaher’s bioprocessing segment shows consistent growth, and the upcoming patent cliff is expected to provide significant tailwinds, boosting demand for their life science equipment. Valuation analysis indicates the stock is currently undervalued, with potential for significant upside as market conditions improve and growth returns, making it a buy. Read the full article on Seeking Alpha
Seeking Alpha • Jan 15

Danaher Corporation: Question Mark Behind The Moat And Probably Overvalued

Summary Danaher Corporation, a key player in Life Sciences, Biotechnology, and Diagnostics, has shown mixed financial performance with recent declines in revenue and net earnings. Despite recent struggles, Danaher has strong growth potential driven by secular tailwinds like an aging population and technological advancements in diagnostics. The company exhibits a wide economic moat due to high switching costs and stable margins, but its RoIC is below the ideal threshold. Currently, Danaher is overvalued with high P/E and P/FCF ratios, making it a "Hold" rather than a buy, pending future performance improvements. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Danaher: A Wide-Moat Gem I Cannot Buy Enough Of

Summary Danaher boasts a wide-moat business model with mission-critical products and recurring revenue streams, ensuring a durable competitive advantage and long-term growth potential. The company's disciplined M&A strategy and integration capabilities have driven significant value creation, supported by strong secular healthcare trends and a focus on innovation. Despite a modest 0.5% dividend yield, Danaher's 12.4% five-year CAGR and low payout ratio offer substantial growth potential for total return investors. Trading at a reasonable valuation, Danaher is poised for a rebound with expected double-digit EPS growth, making it an excellent choice for long-term accumulation. Read the full article on Seeking Alpha
Seeking Alpha • Dec 10

Danaher: A Resilient And Solid Company With Growth Potential

Summary Danaher has maintained a net earning margin above 15% since 2017. In 2024 Q3, the company had a 36.36% liabilities-to-assets ratio, the lowest level since 2017. Danaher's largest customers have reduced their excess of COVID-19-related products. So, Danaher expects a further boost in its sales. The company has been successful in generating growth through acquiring other companies. In the last ten years, half of Danaher's growth has come due to this strategy. Read the full article on Seeking Alpha
Seeking Alpha • Oct 25

Understanding Danaher's Cautiousness

Summary Danaher reported okay Q3 earnings, with "cautiousness" probably being the best adjective to describe the release. The company has finally returned to growth and forward-looking commentary seems positive, but management seems reluctant to put numbers around their optimism. There might be a reason behind the conservativeness, which I explain in this article. Read the full article on Seeking Alpha
Seeking Alpha • Sep 25

Danaher Q3 Preview: Market Share Gains In Molecular Testing

Summary I reiterate my 'Strong Buy' rating for Danaher, with a one-year price target of $310 per share, citing recovery in bioprocessing and market share gains in molecular testing. Danaher's bioprocessing market shows high-single-digit growth in orders, with stabilization in China, and is expected to sustain recovery in Q3 and FY25. Cepheid's market share gains in molecular testing, including FDA authorization for its Hepatitis C RNA test, highlight Danaher's innovation and growth potential. Despite cautious outlook for China, I project Danaher will outpace market growth, driven by molecular testing, M&A, and margin expansion, with improved capital funding in life sciences. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NYSE:DHR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202828,8506,5206,8978,06615
12/31/202726,9915,7526,1967,43222
12/31/202625,4714,5355,6626,75022
3/27/202624,7783,6755,2916,439N/A
12/31/202524,5683,6005,2606,416N/A
9/26/202524,2683,5035,0176,318N/A
6/27/202524,0133,4134,8626,169N/A
3/28/202523,8203,7654,9026,248N/A
12/31/202423,8753,8995,2966,688N/A
9/27/202423,7423,9344,9786,288N/A
6/28/202423,5684,0565,0816,447N/A
3/29/202423,7374,0695,5486,956N/A
12/31/202323,8904,2005,7817,164N/A
9/29/202321,0264,4086,8428,086N/A
6/30/202323,0655,0197,2578,424N/A
3/31/202324,9045,7577,3648,498N/A
12/31/202226,6436,2227,4018,519N/A
9/30/202231,2506,6407,0688,311N/A
7/1/202230,8166,2067,0518,335N/A
4/1/202230,2836,2067,1628,455N/A
12/31/202124,8025,2837,1188,358N/A
10/1/202128,0655,6367,0568,246N/A
7/2/202126,7205,3616,8767,935N/A
4/2/202124,7994,5956,3517,260N/A
12/31/202022,2843,5105,4176,208N/A
10/2/202020,3923,0834,4445,099N/A
7/3/202018,8862,8533,7124,341N/A
4/3/202018,0342,6143,4394,068N/A
12/31/201917,9112,364N/A3,952N/A
9/27/201915,5622,093N/A4,078N/A
6/28/201916,0372,145N/A4,032N/A
3/29/201916,5732,166N/A3,896N/A
12/31/201817,0492,406N/A4,022N/A
9/28/201819,6152,761N/A3,619N/A
6/29/201819,2902,669N/A3,772N/A
3/30/201818,8192,553N/A3,747N/A
12/31/201715,5192,172N/A3,478N/A
9/29/201717,8282,360N/A3,292N/A
6/30/201717,4322,191N/A3,038N/A
3/31/201717,1642,051N/A3,309N/A
12/31/201616,8822,153N/A3,522N/A
9/30/201616,6211,927N/A4,104N/A
7/1/201616,0011,905N/A4,239N/A
4/1/201613,6631,775N/A4,051N/A
12/31/201514,4341,747N/A3,802N/A
10/2/201515,3351,875N/A3,810N/A
7/3/201516,5302,177N/A3,873N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DHR's forecast earnings growth (19.9% per year) is above the savings rate (3.5%).

Earnings vs Market: DHR's earnings (19.9% per year) are forecast to grow faster than the US market (16.8% per year).

High Growth Earnings: DHR's earnings are forecast to grow, but not significantly.

Revenue vs Market: DHR's revenue (5.5% per year) is forecast to grow slower than the US market (11.7% per year).

High Growth Revenue: DHR's revenue (5.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DHR's Return on Equity is forecast to be low in 3 years time (11.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/17 04:21
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/27
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Danaher Corporation is covered by 44 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Catherine Ramsey SchulteBaird
Robert CornellBarclays